Funding rounds · Week 37 · 13 September 2026
weekly · 7d window · SEC Form D
All funding rounds editions →$14.8m
$14.8m of $29.6m target
Cloverleaf Bio, Inc.
Cloverleaf Bio is a biotechnology company developing a new class of RNA based cancer therapies. Its research uses engineered RNA molecules to target tumour biology and create treatment candidates with new mechanisms.
- Appearances
- 1
- Categories
- 1
- First seen
- 13 September 2026
- Latest
- 13 September 2026
01/
Appearance history
1 appearanceThis page records every appearance of the same entity in the reviewed RiseFinder exports. Rankings keep the original category, period and measurement direction.
02/
Get email updates
Join the listGet early signals on the websites, apps, repositories and startups gaining momentum. Join the list for Risefinder email briefings.
Be first to receive the briefing.